10x Genomics (TXG) Current Leases (2020 - 2026)

10x Genomics has disclosed Current Leases across 7 years of filings, most recently posting $11.3 million for Q1 2026.

• Current Leases for Q1 2026 came in at $11.3 million, up 19.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.3 million (up 19.98% YoY), and the FY2025 annual result was $11.0 million, up 18.3% from the prior year.
• Current Leases came in at $11.3 million for Q1 2026 at 10x Genomics, up from $11.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $11.5 million in Q4 2023 to a low of $7.6 million in Q1 2022.
• The 5-year median for Current Leases is $9.4 million (2025), against an average of $9.7 million.
• Across the five-year window, Current Leases surged 88.02% in 2022 and dropped 19.4% in 2024, its largest moves.
• 10x Genomics' Current Leases stood at $9.0 million in 2022, then gained by 27.49% to $11.5 million in 2023, then fell by 19.4% to $9.3 million in 2024, then gained by 18.3% to $11.0 million in 2025, then climbed by 3.14% to $11.3 million in 2026.
• The last three Current Leases figures came in at $11.3 million (Q1 2026), $11.0 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.